Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryNovember 5, 2018	Minerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates Data readouts from five ongoing late-stage trials expected in 2019 WALTHAM, Mass. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today	View HTML PDF Version
Toggle SummaryNovember 6, 2017	Minerva Neurosciences Reports Third Quarter 2017 Financial Results and Business Updates WALTHAM, Mass. , Nov. 06, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter	View HTML PDF Version
Toggle SummaryNovember 3, 2016	Minerva Neurosciences Reports Third Quarter 2016 Financial Results and Business Updates Management to host conference call today at 8:30 a.m. Eastern Time	View HTML Minerva Neurosciences Reports Third Quarter 2016 Financial Results and Business Updates 44 KB
Toggle SummaryNovember 5, 2015	Minerva Neurosciences Reports Third Quarter 2015 Financial Results and Business Updates	View HTML Minerva Neurosciences Reports Third Quarter 2015 Financial Results and Business Updates 33 KB
Toggle SummaryNovember 6, 2014	Minerva Neurosciences Reports Third Quarter 2014 Financial Results	View HTML Minerva Neurosciences Reports Third Quarter 2014 Financial Results 32 KB
Toggle SummaryAugust 9, 2022	Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates Company Continues to Prepare for Potential Submission of an NDA for Roluperidone in the Third Quarter of 2022 WALTHAM, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat	View HTML PDF Version
Toggle SummaryAugust 2, 2021	Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates WALTHAM, Mass. , Aug. 02, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the	View HTML PDF Version
Toggle SummaryAugust 3, 2020	Minerva Neurosciences Reports Second Quarter 2020 Financial Results and Business Updates WALTHAM, Mass. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the	View HTML PDF Version
Toggle SummaryAugust 5, 2019	Minerva Neurosciences Reports Second Quarter 2019 Financial Results and Business Updates During the Second Quarter, Minerva announced several important clinical advancements, including positive top line results from two Phase 2b studies of seltorexant (MIN-202) in major depressive disorder (MDD) and insomnia Patient enrollment progresses in pivotal Phase 3 trial of roluperidone	View HTML PDF Version
Toggle SummaryAugust 2, 2018	Minerva Neurosciences Reports Second Quarter 2018 Financial Results and Business Updates Five ongoing late-stage trials on track for data readouts in 2019 WALTHAM, Mass. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today	View HTML PDF Version

Press Releases

Shareholder Tools